国际眼科纵览
• 综述 • 上一篇 下一篇
刘朝辉 高晓虹 栗改云 马涛 李康
收稿日期:
出版日期:
发布日期:
通讯作者:
LIU Zhao-hui1, GAO Xiao-hong2, LI Gai-yun2, MA Tao2, LI Kang2
Received:
Online:
Published:
Contact:
摘要:
随着糖尿病视网膜病变(diabetic retinopathy, DR)发病机制的深入研究,目前对DR的药物治疗取得了一定的成果,包括糖皮质激素、抗血管内皮细胞生长因子、抗血小板源性生长因子、非甾体类消炎药以及改善视神经功能的药物。目前治疗糖尿病黄斑水肿,玻璃体注药治疗特别是抗血管内皮细胞生长因子药物已逐渐推广。
Abstract:
With the update of the pathologic mechanisms of diabetic retinopathy (DR), currently medication therapy has also made some progress, including corticosteroids, anti-vascular endothelial growth factor, anti-platelet derived growth factor, non-steroidal anti-inflammatory drugs, as well as drugs to improve the function of the optic nerve. Currently, in the treatment of diabetic macular edema, intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity.
刘朝辉 高晓虹 栗改云 马涛 李康. 糖尿病视网膜病变药物治疗的研究进展[J]. 国际眼科纵览, doi: 10.3760/ cma.j.issn.1673-5803.2016.04.012.
LIU Zhao-hui1, GAO Xiao-hong2, LI Gai-yun2, MA Tao2, LI Kang2. Progress in medication for diabetic retinopathy[J]. International Review of Ophthalmology, doi: 10.3760/ cma.j.issn.1673-5803.2016.04.012.
0 / / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: http://www.j-bio.net/CN/10.3760/ cma.j.issn.1673-5803.2016.04.012
http://www.j-bio.net/CN/Y2016/V40/I4/272